Your browser doesn't support javascript.
loading
Neuropsychological functioning of patients with major depression or bipolar disorder comorbid to substance use disorders: A systematic review.
Miguel, Nuria; Marquez-Arrico, Julia E; Jodar, Mercè; Navarro, José Francisco; Adan, Ana.
Afiliación
  • Miguel N; Department of Clinical Psychology and Psychobiology, Universitat de Barcelona, Spain.
  • Marquez-Arrico JE; Department of Clinical Psychology and Psychobiology, Universitat de Barcelona, Spain; Institute of Neurosciences (UBNeuro), Universitat de Barcelona, Spain.
  • Jodar M; Neurology Service, Hospital Universitari Parc Taulí, Sabadell, Spain; Department of Clinical and Health Psychology, Universitat Autònoma de Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud mental (CIBERSAM), Instituto de salud Carlos III, Madrid, Spain.
  • Navarro JF; Department of Psychobiology, School of Psychology, University of Málaga, Spain.
  • Adan A; Department of Clinical Psychology and Psychobiology, Universitat de Barcelona, Spain; Institute of Neurosciences (UBNeuro), Universitat de Barcelona, Spain. Electronic address: aadan@ub.edu.
Eur Neuropsychopharmacol ; 75: 41-58, 2023 Oct.
Article en En | MEDLINE | ID: mdl-37453267
Major depression disorder (MDD) and bipolar disorder (BD) are usual comorbidities in patients with substance use disorders (SUD), a condition known as dual disorder (DD). MDD, BD and SUD are associated with cognitive impairment, potentially leading to a greater functional impairment in the context of DD. OBJECTIVES: To review the existing data on the cognitive impairment in DD patients with comorbid MDD or BD, considering the influence of the depressive symptomatology. METHODS: Following the PRISMA protocol 19 studies were selected from the last 17 years, 13 of which focused on BD, five on MDD and one included both diagnoses. RESULTS: Studies based in BD+SUD showed that the most affected cognitive domains were attention and executive functions, but not all of them found a greater impairment due to the comorbidity. While fewer studies were found for depression, MDD+SUD works point to a similar impairment cognitive pattern. Furthermore, depression improvement could be associated to better cognitive performance. LIMITATIONS: More standardized research is needed regarding the influence of depression on cognitive performance of DD patients, especially on those with comorbid MDD. Factors such as main substance, abstinence, or MDD/BD-related variables should be considered. Unstudied factors, like gender or circadian rhythms, are proposed to improve knowledge in this area. CONCLUSIONS: Current studies suggest that DD could potentiate cognitive impairment in BD, MDD and SUD. However, additional research is needed to improve the understanding of comorbidity to apply more individualized therapies in the treatment of these patients, considering the interference of their neurocognitive functioning.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Systematic_reviews Idioma: En Revista: Eur Neuropsychopharmacol Asunto de la revista: PSICOFARMACOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: España Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Systematic_reviews Idioma: En Revista: Eur Neuropsychopharmacol Asunto de la revista: PSICOFARMACOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: España Pais de publicación: Países Bajos